In severe eosinophilic asthma controlled with benralizumab, tapering high-dose ICS reduced dose while maintaining control.

Stanbrook, Matthew B

Stanbrook, Matthew B.

Affiliation

Stanbrook MB; Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada (M.B.S.).

Ann Intern Med ; 177(4): JC43, 2024 04.

Article in En | MEDLINE | ID: mdl-38560905

ABSTRACT

ABSTRACT

SOURCE CITATION Jackson DJ, Heaney LG, Humbert M, et al; SHAMAL Investigators. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL) a randomised, multicentre, open-label, phase 4 study. Lancet. 2024;403271-281. 38071986.

Subject(s)

Anti-Asthmatic Agents; Asthma; Humans; Adrenal Cortex Hormones/therapeutic use; Anti-Asthmatic Agents/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Antibodies, Monoclonal, Humanized/adverse effects; Asthma/drug therapy; Disease Progression; Randomized Controlled Trials as Topic; Multicenter Studies as Topic

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Anti-Asthmatic Agents Limits: Humans Language: En Journal: Ann Intern Med Year: 2024 Type: Article

Fulltext

XML

PubMed Links

Search on Google